Stephanie Illich Stroll, Founder and Executive Director, is a biotech entrepreneur with a deep commitment to innovation and impact. She launched her first 3D bioprinting startup at just 20, and has since acquired expertise in cardiovascular regenerative medicine, tissue engineering and AI through her research and training at Harvard Medical School/Beth Israel Deaconess Medical Center, Weizmann Institute for Science, MIT and UMass Lowell. Her regulatory acumen spans FDA and EMA compliance, focusing on the 21st Century Cures Act and regenerative therapies. Her work as an Advisory Board Member to the Regenerative Outcomes Foundation highlights her dedication to safe, effective pathways to approval. She served as a Clinical Research Coordinator and Business Development Consultant at Regenerative Outcomes LLC and SANA Holdings, and was involved in Ukrainian regenerative clinical trials for traumatic war injuries and thermal burns. With over a decade of experience in 3D bioprinting, Stroll also leads workshops for medical professionals and is a member of the Association for Clinical Research Professionals (ACRP). Stroll holds certificates in Lean Six Sigma Black Belt, Pharmaceutical Project Management, Clinical Trials Project Management, AI for Drug Discovery and AI in Biotech and Pharma. She holds an additional 10 internationally recognized certifications in the medicinal cannabis industry, covering the U.S., Canada, and Europe in regulatory compliance, cannabis law, and business strategy. Her blend of entrepreneurial vision, regulatory expertise, and commitment to patient safety fuels her leadership at Boston Biotech Advisors to bring products to market faster and with improved compliance.